Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-IFNAR monoclonal antibody
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
An anti-IFNAR monoclonal antibody is a type of biologic therapy designed to target and block the Type I Interferon Receptor (IFNAR), specifically the IFNAR1 subunit. By binding to IFNAR, these antibodies inhibit the signaling of all type I interferons (including various IFN-alpha subtypes, IFN-beta, and IFN-omega). This blockade prevents the downstream activation of the JAK-STAT pathway, thereby reducing the expression of interferon-stimulated genes (ISGs) and suppressing the inflammatory and autoimmune responses associated with type I interferon pathway upregulation. Clinically, this mechanism is utilized in the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE), where anifrolumab (Saphnelo) is an approved anti-IFNAR1 monoclonal antibody. In preclinical research, anti-IFNAR antibodies (such as the mouse-specific clone MAR1-5A3) are widely used to study the role of type I interferons in viral infections, transplant rejection, and autoimmune pathogenesis.
- Other names
- anti-IFNAR antibodyanti-IFNAR mAbanti-IFNAR1 monoclonal antibodyanti-IFNAR-1 monoclonal antibodyanti-IFNAR 1 monoclonal antibodyanti-interferon alpha/beta receptor 1 monoclonal antibody
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on anti-IFNAR monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-IFNAR monoclonal antibody.